At a glance
| Sequence shorthand | Pal-VGVAPG |
|---|---|
| Structural context | Elastin-related sequence |
| Research focus | Self-assembly and skin interactions |
| Recent model | Excised human skin and laboratory assays |
| Clinical limitation | Durable visible benefit not established broadly |
Overview
This ingredient attaches a palmitoyl group to the sequence valine-glycine-valine-alanine-proline-glycine. The fatty-acid modification influences how the molecule behaves in formulations and interacts with skin structures. It is often discussed as an elastin-related signaling peptide, but newer research also considers its physical self-assembly into organized structures. Those are distinct possible explanations for measured effects. A change in skin mechanics or water distribution can occur without proving production of new functional elastic fibers in living people. Molecular identity and experimental tissue measurements are well-defined research questions, while direct clinical evidence for specific visible outcomes remains considerably more limited.
How it works
A 2025 study tracked palmitoyl hexapeptide-12 in human skin layers and examined how it self-assembles and interacts with native skin components. Such work suggests possible physical effects on barrier properties and hydration alongside traditional signaling hypotheses. It does not show that the ingredient acts as replacement elastin. The behavior of a particular sol or gel preparation also cannot be assumed for every cream containing it.
What the 2025 study adds
Researchers used chemical imaging and mechanical methods to track the peptide in skin layers and examine its interactions with tissue components. They reported penetration into stratum-corneum and epidermal regions and changes in a deliberately altered barrier model. This is direct experimental work, but not a randomized facial trial or evidence of long-term wrinkle reduction.
Supporting sources [1]
Why sequence and preparation matter
The CIR assessment identifies the palmitoylated hexapeptide and distinguishes it from unmodified hexapeptide-12 and other peptide derivatives. Altering the lipid group, sequence, or physical formulation changes the material being tested. A general peptide label cannot preserve those distinctions on its own.
Supporting sources [2]
Scope of a cosmetic assessment
Cosmetic safety assessments concern described topical practices, not systemic injection or unlimited use. Cosmetic status is not FDA drug approval. The recent experimental findings should motivate product-specific testing of tolerability and appearance outcomes rather than an unsupported claim that all elastin-related benefits have been clinically demonstrated.
Reading this profile
Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Palmitoylated elastin-sequence hexapeptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Palmitoyl hexapeptide-12 in human skin layers: imaging and mechanical study ↗Original research · Checked 2026-10-27
- CIR final safety assessment: tripeptide-1, hexapeptide-12, derivatives, and palmitoyl tetrapeptide-7 ↗Ingredient assessment · Checked 2026-10-27
- FDA: authority over cosmetics and the distinction from drug approval ↗Regulatory source · Checked 2026-10-27